Skip to main content
锦波生物 logo

锦波生物 — Investor Relations & Filings

Ticker · 920982 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2024-01-07 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920982

About 锦波生物

https://www.sxjbswyy.com/

Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. specializes in the research, development, and manufacturing of functional proteins through synthetic biology. The company is recognized for its industrialization of recombinant humanized collagen, specifically Type III collagen with a stable triple helix structure. Its core business encompasses the production of medical-grade biomaterials, functional skincare products, and medical devices used in aesthetics, wound healing, and gynecological health. By utilizing advanced protein engineering, the company provides biocompatible solutions designed for tissue repair and anti-aging applications. Its technical focus remains on the structural optimization and large-scale production of high-purity recombinant proteins to meet clinical and consumer health demands.

Recent filings

Filing Released Lang Actions
第三届监事会第二十一次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of a supervisory board meeting resolution, specifically about the election of a new chairman of the supervisory board due to retirement of the previous chairman. It includes details about the meeting date, attendance, and voting results. There is no financial data, no mention of annual or interim reports, no audit information, no earnings data, and no regulatory certifications. The content focuses on board/management changes, specifically the election of a new supervisory board chairman. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication but a substantive announcement of a management change.
2024-01-07 Chinese
2023年第六次临时股东大会法律意见书
Regulatory Filings
2024-01-01 Chinese
2023 年第六次临时股东大会决议公告
Board/Management Information Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the 2023 sixth extraordinary general meeting of shareholders of Shanxi Jinbo Biopharmaceutical Co., Ltd. It includes information about the meeting's convening, attendance, agenda items, voting results, and changes in board and supervisory personnel. The document focuses on board and management changes, specifically the resignation of a supervisory board chairman and the appointment of a new supervisor. There is no financial data or report content, but rather a formal announcement of management changes and meeting resolutions. Therefore, the document fits the category of Board/Management Information (MANG). The document length is 1871 characters, which is consistent with an announcement rather than a full report.
2024-01-01 Chinese
关于山西锦波生物医药股份有限公司以自筹资金预先投入募集资金投资项目和支付发行费用的鉴证报告
Regulatory Filings
2023-12-11 Chinese
关于使用募集资金置换预先投入募投项目及已支付发行费用的自筹资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement by Shanxi Jinbo Biopharmaceutical Co., Ltd. regarding the use of raised funds to replace self-raised funds previously invested in projects and paid issuance expenses. It details the fundraising approval, amounts raised, investment projects, and the company's board and supervisory approvals. The document is a formal disclosure about the use of capital raised from a public offering, including compliance with regulatory requirements and opinions from auditors and sponsors. It does not contain financial statements or detailed financial performance data, nor is it a transcript, report, or presentation. It is a regulatory announcement about capital usage and fund management related to financing activities. Therefore, it fits best under Capital/Financing Update (CAP). The document length is 3776 characters, which is sufficient for a detailed announcement but not a full report. No indication that it is merely a report publication announcement or certification. Hence, the classification is CAP with high confidence.
2023-12-11 Chinese
关于召开2023年第六次临时股东大会通知公告（提供网络投票）
Regulatory Filings Classification · 95% confidence The document is a notice announcing the convening of the 2023 sixth extraordinary general meeting of shareholders (临时股东大会) of Shanxi Jinbo Biopharmaceutical Co., Ltd. It details the meeting date, voting methods, agenda items including the nomination of a new supervisor, and procedural information for shareholders. It does not contain financial statements or results, nor is it a transcript or report of the meeting outcomes. It is a formal announcement of a shareholders meeting, not the meeting materials or results themselves. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since it is a notice of the meeting itself and not a solicitation or proxy statement, and not the voting results, it is best classified as a Regulatory Filing (RNS) as a general regulatory announcement. The document length is short (2345 characters), and it is an announcement of a meeting, not a report or results. Hence, Regulatory Filings (RNS) is the most appropriate category.
2023-12-11 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.